Novozymes A/S (OTCMKTS:NVZMY) Stock Short Interest Drops 64.7%

Novozymes A/S (OTCMKTS:NVZMY) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 12,081 shares, a decrease of 64.7% from the August 31st total of 34,196 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 39,198 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Novozymes A/S

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B lifted its stake in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. 0.03% of the stock is owned by hedge funds and other institutional investors.

Novozymes A/S Stock Down 3.6%

Shares of NVZMY stock traded down $2.41 during trading hours on Friday, reaching $65.02. 23,418 shares of the stock were exchanged, compared to its average volume of 21,917. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $75.27. The business’s fifty day moving average is $66.63 and its two-hundred day moving average is $62.07. The firm has a market capitalization of $26.95 billion, a P/E ratio of 41.15, a P/E/G ratio of 2.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.74 and a quick ratio of 1.03.

Novozymes A/S (OTCMKTS:NVZMY) last posted its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%.The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.27 billion. As a group, research analysts expect that Novozymes A/S will post 2.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.